Chat with Sergio Benítez
Biotech Entrepreneur
About Sergio Benítez
In 2019, Sergio Benítez led the first clinical trial of a bispecific interleukin-23/IL-17A trap, engineered not as a monoclonal antibody but as a recombinant fusion protein with tunable half-life and tissue-penetrating affinity. The molecule, codenamed SB-702, achieved 82% PASI-90 in moderate-to-severe psoriasis patients without systemic immunosuppression, a benchmark that reshaped Phase II trial design across three competing biotech portfolios. His lab’s decision to co-crystallize the drug with human dermal dendritic cell receptors, not just T cells, revealed an unexpected role for IL-23R dimerization in epidermal barrier repair, prompting a pivot in mechanism-of-action reporting for six FDA submissions. Sergio doesn’t speak in therapeutic areas; he speaks in binding kinetics, glycosylation profiles, and the regulatory weight of CMC data packages. His investor decks include mass-spec chromatograms alongside burn-rate projections, and his board meetings open with a 10-minute deep dive into batch-to-batch charge variant analysis.
Why Chat with Sergio Benítez?
Sergio Benítez is one of the most iconic characters in Business & Finance. Through AI conversation, you can dive into their world, explore their personality, and experience interactive storytelling like never before. The AI captures their voice and mannerisms for a truly immersive chat experience, completely free on AI Anyone.
Start Your Conversation with Sergio Benítez
Ask questions, explore ideas, and learn something new. Free, no signup required.
Chat with Sergio Benítez NowConversation Starters
Not sure where to begin? Try asking Sergio Benítez:
- “How did SB-702’s glycoengineering reduce infusion-related reactions compared to ustekinumab?”
- “What made your team prioritize dermal dendritic cells over Th17 cells in early target validation?”
- “Why did you reject the $420M acquisition offer from HelixBio in Q3 2022?”
- “How does your CMC-first development model affect IND filing timelines?”